	Patient 1	Patient 2	Patient 3
Age at diagnosis (years)	50	53	62
Sex	M	M	M
Primary tumor	small bowel	stomach	small bowel
Primary resected	no	yes	yes
Mutational status	KIT (exon 11)	KIT (exon 11)	wild type
Metastasis at diagnosis	yes	no	no
Previous systemic treatments	2 lines	2 lines	2 lines
PS ECOG at the start of rego	2	1	2
Previous standard schedule of rego	yes	yes	yes
AEs ≥ G2 with standard schedule	no	yes ¹	yes²
Duration of standard schedule (months)	8	12	3.3
Reason for modified schedule	+ symptoms during the week-off	toxicity	toxicity, + symptoms during the week-off
$AEs \ge G2$ with modified schedule	no	no	no
Duration of modified schedule (months)	9	6	6.2
PFS with rego (months)	17	19.3	9.5
Progression during rego	yes	no	no
Subsequent lines	imatinib	no	no
FU since start of rego (months)	20.3	19.3	9.5
FU since diagnosis (months)	58	146	31
Patient's status at the last FU Table 1s Patients' sharesteri	dead	alive, progression-free	alive, progression-free

Table 1: Patients' characteristics

¹ hypothyroidism G2, anemia G3, nausea G2, anorexia G2, sialorrhea G2

² anemia G3, hypothyroidism G2